Cerebrolysin is a brain-derived peptide complex consisting of low-molecular-weight neuropeptides (25%) and free amino acids (75%), produced by enzymatic hydrolysis of purified porcine brain proteins. All peptide fragments are below 10 kDa, allowing them to cross the blood-brain barrier. It is approved in over 40 countries (Europe, Asia, Russia) for stroke, traumatic brain injury, and dementia, but is NOT FDA-approved in the United States. Clinical evidence is mixed — some trials show benefit in stroke recovery while a 2023 Cochrane review found no clear mortality benefit.
Category: Nootropic / Neuroprotective. Evidence rating: C (early/mixed human evidence).
Clinical status: Approved as prescription drug in 50+ countries (Austria, Russia, China, South Korea, and others). Not FDA-approved. Over 150 clinical trials with >7,000 patients.
Cerebrolysin provides multimodal neuroprotection through several pathways: it enhances neurogenesis and neuroplasticity via activation of PI3K/AKT and Sonic Hedgehog (Shh) signaling, promotes synaptic remodeling through CREB phosphorylation and BDNF-like activity, inhibits calpain-mediated…
Research base: 26 registered clinical trials and 103 indexed publications reference Cerebrolysin.
Safety considerations: Generally well-tolerated in clinical trials; Common: dizziness, headache, injection site reactions; Rare: agitation, fever, flu-like symptoms.
Reviewed by the PeptideAtlas Editorial Team. Last reviewed: 2026-07-05.
Related peptides: Semax, Pinealon, Cortagen.
Compare: Cerebrolysin vs Semax, Cerebrolysin vs Pinealon, Cerebrolysin vs Cortagen.
Cerebrolysin has never undergone the FDA approval process. The manufacturer (EVER Pharma, Austria) has focused on European and Asian markets. The mixed clinical evidence (positive in some trials, negative in others) would make FDA approval challenging without additional large-scale trials.
It has been used clinically for over 40 years in 40+ countries with a generally good safety record. However, it is derived from porcine brain tissue (theoretical prion concerns), may lower seizure threshold, and a 2023 Cochrane review noted some safety signals. It should only be used under medical supervision.
Cerebrolysin is a mixture of peptides and amino acids derived from pig brain tissue, researched extensively for neurotrophic and neuroprotective effects, particularly in cognitive recovery.
CEREBROLYSIN has been studied for: Cognitive support, Brain recovery, Neuroprotection, Memory research. Neurotrophic factors; brain recovery research.
Contains neurotrophic factors that may support neuronal survival, synaptic plasticity, and neurogenesis.